Entrepreneurs say the FDA is killing medical innovation
Editor's Pick Venture capital is drying up for early-stage medical devices. Experts say that American patients are already "missing out" on the most innovative treatment options.
Editor's Pick Venture capital is drying up for early-stage medical devices. Experts say that American patients are already "missing out" on the most innovative treatment options.
The Office of the National Coordinator for Health IT just released its budget plan for 2014, which would increase its funding. But it's a little-reported line item that's causing a stir among entrepreneurs -- a proposal to boost fees for electronic health record vendors.
Editor's Pick A lack of clarity from government is stifling innovation in the health IT sector.
Congress is conducting a three-day series of hearings to decide how to regulate the explosion of health apps on smartphone and tablet devices.
The Food and Drug Administration is being accused of monitoring the personal e-mails of six employees who had previously reported inappropriate device approvals to Congress and the press.
“Whistleblowers” are protected by law in order to ensure that employees feel …
In February 2011, Mobisante got the green light from the U.S. Food and Drug Administration for its mobile, smartphone-powered ultrasound device. It took the medical device startup another eight months to meet the various FDA guidelines, but now its MobiUS …
The push to create a regulatory framework for generic versions of biotech drugs fizzled last year in Congress, as legislators seemed to lose interest after failing to attach the measure to a major FDA reform bill. But now it’s back, …
(UPDATED: See below.)
Medical-device startups are booming these days, as VCs throw money at everything from artificial spinal-disc fillers to implantable weight-control “neuromodulators” to vacuum devices that suck blood clots out of blocked vessels. (That appears to be in …
(UPDATED: See below.)
Personalized medicine — the idea that doctors will one day tailor your medical care based on your genetic profile — has been a long time coming, as I’ve previously written. As it turns out, that’s no …
(UPDATED: See below.)
Catching up on a few life-science related items you may have missed over the weekend:
If you prick a cyborg, does he not bleed? — The WaPo’s Joel Garreau brings us this fascinating story about Peter …
Flip switch for stem cells – Three research teams reported a technique for “reprogramming” skin cells into embryonic stem cells, those primordial bits of protoplasm that can propagate themselves indefinitely and, under the right conditions, transform themselves into any type …
The first time you hear it, “evidence-based medicine” sounds like one of those goofily redundant phrases like “animated cartoon” or “past experience.” Aren’t doctors always carrying out studies of one sort or another? Isn’t medicine evidence-based already?
Well, no, not …
The Senate passed a bill that requires the FDA to monitor the safety of drugs more rigorously once they’re on the market, but punted on other proposals that would have allowed the legal import of drugs from other countries and …
No nukes in lymphoma treatment – Two innovative biotech drugs that target tumor cells for destruction by tiny radioactive particles are struggling in the marketplace, in part because cancer doctors are simply too specialized to make proper use of them. …
(Note: This item has been copied over to the Life Sciences page from its original location on the VentureBeat main page. To view it in its original context, with comments, click here.)
A second legislative fight for the biotech industry …
A second legislative fight for the biotech industry is shaping up in Washington over whether to give the Food and Drug Administration authority to approve “generic” versions of biotechnology drugs whose patents have expired.
Measures that would grant FDA that …